Collect blood samples and associated clinical data prior to, during, and post radiation treatment.
In order to further refine and independently validate the performance of DxTerity's test developed during the previous pilot study, the study will collect pre-, during, and post-irradiation blood samples and associated clinical and self-reported information from up to five hundred (500) subjects for analysis. Patients with a diagnosis of primary gastrointestinal (GI), genitourinary (GU), or gynecological (GYN) cancer requiring radiation treatment to the primary disease site will be included in the study. Combining chemotherapy is allowed. Blood samples for this study will be collected from cancer patients scheduled to undergo radiation therapy prior to and either during or after treatment. Approximately 150μL of blood per time point will be obtained via fingerstick remotely, from the participant's home or doctor's office; participation in this study will not affect any aspect of patient treatment. Samples will be collected using DxTerity's proprietary DxCollect® MCD Fingerstick Kit (MCD).
Study Type
OBSERVATIONAL
Enrollment
16
DxTerity Diagnostics
Compton, California, United States
21st Century Oncology
Bradenton, Florida, United States
21st Century Oncology
Fort Myers, Florida, United States
21st Century Oncology
Plantation, Florida, United States
Obtain pre- and post-irradiation participant-collect blood samples
Obtain pre-irradiation participant-collected blood sample and associated clinical data from cancer patients undergoing abdominal/pelvic radiation therapy as part of clinical care.
Time frame: 1.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.